US expected to impose 100% tariffs on certain drugs: report
The administration of United States President Donald Trump is preparing to impose 100% tariffs on certain drugs. The Financial Times reports that the tariffs could be announced later today and will be applied to pharma companies that have not reached an agreement with the White House.
+Get the most important news from Switzerland in your inbox
The new duties would be imposed through Section 232, which provides for the launch of an investigation before deciding whether to approve them.
In December 2025, Trump announced agreements with nine pharmaceutical firms, including Switzerland’s Novartis and Genentech (a subsidiary of Swiss giant Roche), to reduce the price on certain medical products.
More
Swiss pharma’s global success meets worries at home
As part of the agreement, Novartis would commit to implementing several measures to support the US government’s priorities to contain drug prices. These include a commitment to bring new medicines to high-income countries at comparable prices.
Among the firms that have reached agreements with the White House to increase investments in the US and reduce drug prices in return for a truce on tariffs are Pfizer, AstraZeneca, Eli Lilly and Novo Nordisk.
Translated from Italian with AI/gw
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
External Content
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.